Business Model – The Cal-X Stars Business Accelerator, Inc. business model is that they get 9% anti-dilutive seed equity ownership in startups and innovation platforms that enter their Accelerator Membership Agreement https://calxstars.com/accelerator-membership-agreement/ for providing a variety of startup launch and innovation acceleration support services through a first in human study. They have pre-emptive right to purchase up to 20% equity ownership stakes in these startups right up to graduation.
Leonhardt’s Launchpads powered by Cal-X Stars Business Accelerator, Inc. is both the R&D shared resources incubator and innovation accelerator arm of Leonhardt Ventures LLC. The Leonhardt team has been developing breakthrough medtech innovations since the 1980s with PolyCath in 1988, TALENT stent graft, StentValve, RadiCath, ProCell, DeltaVein, BioPace, Valvublator and PENSIL in the 1990s. Leonhardt led a team in Melbourne, Australia that completed the landmark first aortic aneurysm repair with percutaneous delivery working with Dr. Ken Thomson at the Royal Melbourne Hospital. Their stent graft has world leading market share today for non-surgical repair of aortic aneurysms as part of Medtronic. MyoCell, MyoCath, AortaCell, BioLeonhardt, Vascustim (formerly MyoStim Peripheral) in the 2000’s. In early 2001 Leonhardt led a team that completed the historic first muscle stem cell repair of a a human heart without surgery working with Dr. Patrick Serruys and Dr. Doris Taylor in The Netherlands. Leonhardt’s Launchpads was launched in 2008 in Santa Rosa, California as a biotech medtech incubator and Cal-X Stars Business Accelerator, Inc. in Santa Monica in 2013 as an innovation accelerator. The two merged in late 2016 and now focus on leveraging the Leonhardt core IP in bioelectrics, biologics and endovascualr delivery systems with over 38 breakthrough applications in development https://leonhardtventures.com/development-pipeline/.
Cal-X Stars Business Accelerator, Inc. spun out Cal-Impact in 2018 www.cal-impact.com forming a separate innovation accelerator focused on social good impact innovations. The team has over 600 patent claims issued, pending, in process, optioned or licensed for organ regeneration and recovery – https://patents.justia.com/inventor/howard-j-leonhardt. Over 600,000 patients have been treated with Leonhardt inventions to date.
Leonhardt’s Launchpads founded in 2008 is an R&D lab incubator primarily for Leonhardt Ventures LLC inventions and Cal-X Stars Business Accelerator, Inc. incorporated in 2013 provides classic startup launch accelerator type mentorship and shared resources services to help startups launch and innovations to advance to be ready to be licensed, purchased or to raise capital to advance further down the road. In 2016 the two entities began collaborating more closely as Cal-X Stars Business Accelerator, Inc. began extending selected management and financial support services to Leonhardt’s Launchpads.
Leonhardt’s Launchpads powered by Cal-X Stars Business Accelerator, Inc. focuses on applying the Leonhardt Ventures LLC core IP in bioelectrics, biologics and endovascular delivery systems to organ regeneration and healing forming a separate innovation asset, Licensable Technology Platform, or startup for each organ or purpose specific application.
Leonhardt’s Launchpads focuses in these areas:
Heart & Cardiovascular – Click Here (9 innovations/startups under development)
Brain – Click Here (7 innovations/startups under development)
Cosmetic and Personal Care > Click Here (10 innovations/startups under development – – 4 are spins outs of DentaCell Accelerator Click Here and accelerator within our accelerator focused on dentistry and orthodontics)
Major Organ Regeneration > Click Here (10 innovations/startups under development)
Cancer – Click Here (1 innovation/startup under development)
Warning – Due to early stage nature of these developments with un-proven technologies investments have to be considered in the highest risk category for total loss. Investments are limited to verified accredited investors only with experience in this space. Patents pending may not be issued. Patents issued or licensed may not be maintained. Early data may not hold up in larger studies. Regulatory obstacles are daunting. Company is undercapitalized and under-staffed to accomplish the goals is seeks to accomplish. Company relies on outside suppliers which may not be reliable. Most studies are conducted OUS and data may not be accepted by the FDA. Similar innovation accelerators have only a 4 to 10% success rate in converting early stage innovations into commercial successes.
Innovation Accelerator Business Model = Accelerate each organ or purpose specific application of our core IP through first in human studies of product deemed ready to go to commercialization and then seek out a strategic acquirer/partner to take that innovation all the way to market. Innovation accelerator starts off owning 9% dilution floor equity in each innovation asset and has pre-emptive right to purchase up to 20% share ownership position right up to exit or graduation from the accelerator.
Master IP and Product Development Agreement > Click Here
Accelerator Membership Agreement > Click Here
Our innovation asset valuations are generally substantially below the industry averages for our stage of developments reported in the Wilson Sonsini Click to Read Article an indicator of good value for potential investors.
As a guide in biotech/medtech valuations…
1. Seed round is generally lab research stage = $9 million valuation
2. Series A is small animals = $30 million valuation
3. Series B is large animals = $65 million valuation
4. Series C+ is clinical stage of development starting usually with OUS first in human studies. = $225 million valuation
OUR COMPANIES
IMPORTANT LEGENDS (ANY POTENTIAL INVESTOR PLEASE READ)
Securities offered under Rule 506(c) may be purchased only by accredited investors = persons with > $1 million in assets excluding their home and vehicles or whom have income > $200,000 the past two years consecutively or > $300,000 income as a couple. Accreditation status must be verified via documentation of credible third parties in a position to provide accurate verification. Investors in this offering should have experience in making early stage investments.
Cal-X Stars Business Accelerator, Inc. develops early stage innovations and startups. By nature the risk is very high for these type of investments. Any investor should be fully prepared without reserve to lose all their investment. Our high focus on developing implantable devices and biologics for treating heart failure add exceptionally higher levels of risk as the products require multiple stages of clinical trials costing many millions of dollars and require high intellectual property protection to succeed commercially. The patent landscape in these areas of participation are wrought with potential for litigation. A high number of clinical trials in the heart failure space fail to prove greater safety and efficacy compared to currently available choices. A high number of early seed stage innovations fail to ever make it to market and even a smaller number become commercial successes. This type of investment is NOT appropriate for nest egg savings.
• The securities are being offered in reliance on an exemption from the registration requirements of the 150Securities Act and are not required to comply with specific disclosure requirements under the Securities Act; the Commission has not passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials; the securities are subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; and investing in securities involves risk and purchasers should be able to bear the loss of the entire investment. Private funds would be required to include a legend informing investors that the funds are not subject to the protections of the Investment Company Act.
CAUTION Disclaimer and Warning: Products described on this web site are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. Any statement or phrases implying efficacy or safety in any form are considered modified by “intended to” or “designed to”. Investigational use only in countries where investigation is permitted by law and proper filings have been made and appropriate regulatory clearances have been granted. Any use of the product(s) must be in an authorized clinical study with institutional review board (ethics committee) approval and proper patient consent procedures followed. For other countries product is only available for laboratory investigation by credentialed institutions and investigators with proper clearances with a research agreement in place with a study sponsor. NOT AVAILABLE FOR SALE.